JBC INTERFERin siRNA transfection reagent

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M412038200 on November 10, 2004

J. Biol. Chem., Vol. 280, Issue 3, 1982-1991, January 21, 2005
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/3/1982    most recent
M412038200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhang, P.
Right arrow Articles by Lange, C. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, P.
Right arrow Articles by Lange, C. A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Regulated Association of Protein Kinase B/Akt with Breast Tumor Kinase*

Ping Zhang, Julie Hanson Ostrander, Emily J. Faivre, Abby Olsen, Daniel Fitzsimmons, and Carol A. Lange{ddagger}

From the University of Minnesota Cancer Center and the Departments of Medicine, Division of Hematology, Oncology, and Transplantation, and Pharmacology, Minneapolis, Minnesota 55455

Increased protein-tyrosine kinase activity is a prognostic indicator of decreased disease-free survival in patients with advanced breast tumors. Breast tumor kinase (Brk) is a soluble protein-tyrosine kinase overexpressed in the majority of breast cancers and also in normal skin and gut epithelium, but not in normal breast epithelial cells. Herein, we show that Brk interacts with protein kinase B/Akt, a serine/threonine kinase involved in cell growth and survival. Epidermal growth factor (EGF) treatment of human keratinocytes or Brk-transfected COS-1 cells leads to the dissociation of the Brk·Akt complex, whereas a constitutively active Brk mutant containing a point mutation at Tyr-447 (YF-Brk) failed to dissociate from Akt upon EGF treatment. In addition, Brk·Akt dissociation was blocked by the inhibition of phosphatidylinositol 3-kinase. Similar to ectopic Brk, endogenous Brk in T47D breast cancer cells was less phosphorylated upon EGF treatment, but it remained constitutively associated with Akt in the presence of EGF. Overexpression of wild-type (wt)-Brk, kinase-inactive (KM)-Brk, or YF-Brk increased the Tyr phosphorylation of multiple signaling molecules including EGF receptor. However, only wt- and YF-Brk, but not KM-Brk, induced phosphorylation of Akt and inhibited the kinase activity of Akt in unstimulated cells. Similarly, overexpression of wt- or YF-, but not KM-Brk, blocked the phosphorylation of the forkhead transcription factor, a downstream Akt target. These results suggest that Brk may function as a signaling molecule whose kinase activity normally limits the activity of Akt in unstimulated cells. Additionally, these results suggest that in breast cancer cells Brk behaves similarly to a constitutively active Brk mutant (YF-Brk) and associates with tyrosine-phosphorylated proteins in deregulated signaling complexes. Together these data provide clues to the possible proto-oncogenic and oncogenic functions of Brk.


Received for publication, October 25, 2004 , and in revised form, November 10, 2004.

* This work was supported by National Institutes of Health Grant R21DK058347 and American Cancer Society Grant RSG TBE-107800 (to C. A. L.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

{ddagger} To whom correspondence should be addressed: University of Minnesota Cancer Center, 420 Delaware St. SE., MMC 806, Minneapolis, MN 55455. Tel.: 612-626-0621; Fax: 612-626-4915; E-mail: Lange047{at}tc.umn.edu.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Cancer Res.Home page
G. Chakraborty, S. Jain, and G. C. Kundu
Osteopontin Promotes Vascular Endothelial Growth Factor Dependent Breast Tumor Growth and Angiogenesis via Autocrine and Paracrine Mechanisms
Cancer Res., January 1, 2008; 68(1): 152 - 161.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. H. Ostrander, A. R. Daniel, K. Lofgren, C. G. Kleer, and C. A. Lange
Breast Tumor Kinase (Protein Tyrosine Kinase 6) Regulates Heregulin-Induced Activation of ERK5 and p38 MAP Kinases in Breast Cancer Cells
Cancer Res., May 1, 2007; 67(9): 4199 - 4209.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Uddin, A. R. Hussain, A. K. Siraj, P. S. Manogaran, N. A. Al-Jomah, A. Moorji, V. Atizado, F. Al-Dayel, A. Belgaumi, H. El-Solh, et al.
Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival
Blood, December 15, 2006; 108(13): 4178 - 4186.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Lin, Q. Yang, X. Wang, and Z.-g. Liu
The Essential Role of the Death Domain Kinase Receptor-interacting Protein in Insulin Growth Factor-I-induced c-Jun N-terminal Kinase Activation
J. Biol. Chem., August 18, 2006; 281(33): 23525 - 23532.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
A. Haegebarth, W. Bie, R. Yang, S. E. Crawford, V. Vasioukhin, E. Fuchs, and A. L. Tyner
Protein tyrosine kinase 6 negatively regulates growth and promotes enterocyte differentiation in the small intestine.
Mol. Cell. Biol., July 1, 2006; 26(13): 4949 - 4957.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Jain, G. Chakraborty, and G. C. Kundu
The Crucial Role of Cyclooxygenase-2 in Osteopontin-Induced Protein Kinase C {alpha}/c-Src/I{kappa}B Kinase {alpha}/{beta}-Dependent Prostate Tumor Progression and Angiogenesis.
Cancer Res., July 1, 2006; 66(13): 6638 - 6648.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
M. Kasprzycka, M. Majewski, Z.-J. Wang, A. Ptasznik, M. Wysocka, Q. Zhang, M. Marzec, P. Gimotty, M. R. Crompton, and M. A. Wasik
Expression and Oncogenic Role of Brk (PTK6/Sik) Protein Tyrosine Kinase in Lymphocytes
Am. J. Pathol., May 1, 2006; 168(5): 1631 - 1641.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. E. Lukong, D. Larocque, A. L. Tyner, and S. Richard
Tyrosine Phosphorylation of Sam68 by Breast Tumor Kinase Regulates Intranuclear Localization and Cell Cycle Progression
J. Biol. Chem., November 18, 2005; 280(46): 38639 - 38647.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. I. Kim and S.-T. Lee
An Intramolecular Interaction between SH2-Kinase Linker and Kinase Domain Is Essential for the Catalytic Activity of Protein-tyrosine Kinase-6
J. Biol. Chem., August 12, 2005; 280(32): 28973 - 28980.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.